STAT+: After its last deal fell through, a rare disease therapy gets a second chance with Shionogi
After seeing its last deal go bust in the face of regulatory scrutiny, Maze Therapeutics…
Category: biotechnology
Listen: Everything you need to know about H5N1 bird flu
What happens when a common virus jumps from birds to cows? And should we be…
Exact Sciences’ stock tumbles amid worries cancer detection firm’s growth may slow
Exact Sciences reported first-quarter revenues this week that beat market expectations, and the cancer detection…
Q&A with Jennifer Adair, researcher on a mission to increase global access to gene therapies
BALTIMORE — Gene and cell therapies have transformed a handful of devastating disorders in the…
STAT+: Cytokinetics set to pitch its heart drug to physicians — and Big Pharma suitors
This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers…
Yet another big financing round in immunology
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Drug supplies for millions would be jeopardized by U.S. crackdown on China biopharma industry, trade group says
U.S. legislation that would sever ties with Chinese drugmakers would jeopardize the drug supply for…
STAT+: A nonprofit does deals in Brazil and India to make low-cost CAR-T cell therapies widely available
In the latest bid to widen access to medicines, a nonprofit is sending technology and…
Pharma has over $500B in capital for deals
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Opinion: It shouldn’t be easy to buy synthetic DNA fragments to recreate the 1918 flu virus
It should be hard — exceedingly hard — to obtain the synthetic DNA needed to…
.jpg)
Vertex starts gene therapy Casgevy in five patients
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Merck may have a competition for ever-scarce BCG
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: 4 burning questions about Amgen’s obesity drug, a potential Wegovy and Zepbound competitor
Amgen’s comments Thursday that it’s “very encouraged” by interim Phase 2 data for its obesity…
ICER casts doubt on Sarepta’s DMD gene therapy
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Amgen goes all in on injectable obesity drug as it scraps early-stage pill
Amgen said Thursday that it will no longer develop an early-stage obesity pill, and will…
Listen: Controversial brain tissue research, obesity drug sales, and Novartis’ M&A drama
The removal of small amounts of brain tissue from desperately ill patients, done as part…
STAT+: Novo Nordisk defends Ozempic price in face of Senate scrutiny
Novo Nordisk defended the prices of its blockbuster diabetes and obesity drugs Ozempic and Wegovy…
The biotech news you need to read this morning
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Novartis’ $3 billion MorphoSys boondoggle
This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers…
STAT+: Novartis extends radiopharma plans with $1 billion acquisition
Novartis already produces the leading drug in the radiopharmaceutical field. Now, it is devoting even…
The latest government crackdowns on biotech you need to know
Want to stay on top of the science and politics driving biotech today? Sign up to get…
FDA wants to hear your thoughts on advisory committees
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Activist investor Alex Denner, Bioverativ shareholder reach tentative settlement in insider trading case
A tentative settlement has been reached in a long-running shareholder lawsuit that accused health care…
.jpg)
STAT+: House bill aimed at Chinese biotechs is advancing
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Ono Pharmaceutical to acquire Deciphera Pharma, maker of cancer drugs, for $2.4 billion
Ono Pharmaceutical of Japan said Monday it will acquire Deciphera Pharmaceuticals, a Boston-based maker of…
STAT+: Momentum builds for House bill cracking down on Chinese biotechs
WASHINGTON — A House committee plans to mark up next month legislation that would restrict…
STAT+: Bernie Sanders targets ‘outrageously high price’ of Ozempic
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Washington kicks into gear on H5N1
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
STAT+: Profiting from ‘legal’ insider trading isn’t always easy
This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers…
STAT+: Amid layoffs and a hit to earnings, Bristol’s new CEO shares his vision for the future
Christopher Boerner, 53, took over as the chief executive officer of Bristol Myers Squibb last…
STAT+: Takeda is fourth big company to leave BIO since December
WASHINGTON — Takeda Pharmaceuticals has left the biotechnology industry’s main lobbying group, the fourth departure…
STAT+: Biogen’s Alzheimer’s drug launch on ‘steady pace’ as logistical hurdles recede
Biogen on Wednesday reported first-quarter earnings that beat Wall Street expectations largely on reduced expenses….
STAT+: Looking for signs of growth in Biogen’s earnings
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Novo Nordisk’s growth plan
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Listen: A new obesity startup, an acquisition gone wrong, & the future of Teledoc
How does a startup compete with the likes of Eli Lilly and Novo Nordisk in…
STAT+: Taking stock of the frenzied push into autoimmune disease
This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers…
STAT+: 23andme CEO Anne Wojcicki moves to take company private
After a tumultuous experience on the public markets, 23andMe CEO Anne Wojcicki is moving to…
STAT+: Cancer vaccine startup launches with $54 million, Spark veteran as CEO
A new startup focused on creating vaccines for cancers, influenza, and potentially even HIV launched…
STAT+: ARCH, Medicines Co. veterans raise $290 million for in-licensed obesity drugs
After scouring 200 companies’ pipelines — including a few overlooked pharma shelves — a new…
STAT+: Cerevel drug for Parkinson’s disease improved symptom control in trial
Cerevel Therapeutics, a neuroscience biotech that AbbVie is acquiring, reported that its drug for Parkinson’s…
STAT+: How BIO CEO’s cozy relationship with WuXi soured
WASHINGTON — In the photo, the two men are grinning widely: the CEO of WuXi Biologics…
Amylyx’s Relvyvrio data was, as promised, disappointing
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Biohaven’s data delay degrades stock price
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Intra-Cellular reports positive results in depression study aimed at expanding use of antispsychotic medicine
Intra-Cellular Therapies reported positive results Tuesday from a late-stage clinical trial seeking to expand the…
STAT+: A new PIPE lawsuit challenges the fairness of sharing confidential, stock-moving information
The fairness of PIPEs, particularly the preferential sharing of confidential, stock-moving information, is now a…
A two-decade bet on Seagen pays off
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Ultragenyx reports early success with Angelman syndrome drug, backing up 2022 acquisition
Ultragenyx has found early success with its experimental treatment for the rare disease Angelman syndrome,…
STAT+: Can investing in infectious disease pay off? Vir Biotechnology’s tightrope walk shows it’s a struggle
Nearly a decade ago, venture capitalist Bob Nelsen called industry veteran Vicki Sato to pitch…
What about the company Vertex didn’t buy?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Listen: Vertex’s big deal, biotech’s red numbers, & an industry history lesson
How would you spend $13 billion in cash? Is biotech stale? And remember Dendreon? We…